Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine

PURPOSE: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the combination of weekly oxaliplatin × 4, weekly irinotecan × 4 and capecitabine Monday through Friday for 4 weeks of every 6 week cycle in patients with solid tumors; to determine the pharmacokinetic profile...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Chemother Pharmacol
Auteurs principaux: Krishnamurthi, Smitha S., Brell, Joanna M., Hoppel, Charles L., Egorin, Merrill J., Weaver, Karen C., Li, Xiaolin, Ingalls, Stephen T., Zuhowski, Eleanor G., Schluchter, Mark D., Dowlati, Afshin, Cooney, Matthew M., Gibbons, Joseph, Overmoyer, Beth A., Ivy, S. Percy, Remick, Scot C.
Format: Artigo
Langue:Inglês
Publié: 2008
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4788493/
https://ncbi.nlm.nih.gov/pubmed/18414865
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0754-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires